|Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen.|
|PMID: 21606347 Owner: NLM Status: MEDLINE|
|Despite encouraging clinical results with next generation drugs (MDV3100 and abiraterone) that inhibit androgen receptor (AR) signaling in patients with castration-resistant prostate cancer (CRPC), responses are variable and short-lived. There is an urgent need to understand the basis of resistance to optimize their future use. We reasoned that a radiopharmaceutical that measures intratumoral changes in AR signaling could substantially improve our understanding of AR pathway directed therapies. Expanding on previous observations, we first show that prostate-specific membrane antigen (PSMA) is repressed by androgen treatment in multiple models of AR-positive prostate cancer in an AR-dependent manner. Conversely, antiandrogens up-regulate PSMA expression. These expression changes, including increased PSMA expression in response to treatment with the antiandrogen MDV3100, can be quantitatively measured in vivo in human prostate cancer xenograft models through PET imaging with a fully humanized, radiolabeled antibody to PSMA, (64)Cu-J591. Collectively, these results establish that relative changes in PSMA expression levels can be quantitatively measured using a human-ready imaging reagent and could serve as a biomarker of AR signaling to noninvasively evaluate AR activity in patients with CRPC.|
|Michael J Evans; Peter M Smith-Jones; John Wongvipat; Vincent Navarro; Sae Kim; Neil H Bander; Steven M Larson; Charles L Sawyers|
Related Documents :
|21610217 - Between-method differences in prostate-specific antigen assays affect prostate cancer r...
12717837 - Hogg1 ser326cys polymorphism modifies the significance of the environmental risk factor...
24348837 - Granulocytic sarcoma of the breast in acute myeloid leukemia: two case reports.
1212647 - The control of large bowel cancers. present status and it challenges.
11790987 - Molecular alterations in ductal carcinoma in situ of the breast.
20172727 - A vision to optimise the management of primary breast cancer in older women.
|Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2011-05-23|
|Title: Proceedings of the National Academy of Sciences of the United States of America Volume: 108 ISSN: 1091-6490 ISO Abbreviation: Proc. Natl. Acad. Sci. U.S.A. Publication Date: 2011 Jun|
|Created Date: 2011-06-09 Completed Date: 2011-08-26 Revised Date: 2013-06-28|
Medline Journal Info:
|Nlm Unique ID: 7505876 Medline TA: Proc Natl Acad Sci U S A Country: United States|
|Languages: eng Pagination: 9578-82 Citation Subset: IM|
|Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.|
|APA/MLA Format Download EndNote Download BibTex|
Androgens / pharmacology
Antibodies, Monoclonal / chemistry, immunology, pharmacokinetics
Antigens, Surface / genetics*, immunology, metabolism
Cell Line, Tumor
Copper Radioisotopes / pharmacokinetics
Dihydrotestosterone / pharmacology
Gene Expression Regulation, Neoplastic / drug effects
Glutamate Carboxypeptidase II / genetics*, immunology, metabolism
Heterocyclic Compounds, 1-Ring / chemistry
Neoplasms, Experimental / genetics, metabolism, pathology
Phenylthiohydantoin / analogs & derivatives, pharmacology
Positron-Emission Tomography / methods*
Prostate-Specific Antigen / genetics, metabolism
Prostatic Neoplasms / genetics*, metabolism, pathology
Radiopharmaceuticals / immunology, pharmacokinetics
Receptors, Androgen / genetics*, metabolism
Reverse Transcriptase Polymerase Chain Reaction
Signal Transduction / drug effects, genetics*
|P30 CA08748/CA/NCI NIH HHS; P50-CA86483/CA/NCI NIH HHS; R24 CA83084/CA/NCI NIH HHS; R24 CA86307/CA/NCI NIH HHS; R25-CA096945/CA/NCI NIH HHS; //Howard Hughes Medical Institute|
|0/Androgen Antagonists; 0/Androgens; 0/Antibodies, Monoclonal; 0/Antigens, Surface; 0/Copper Radioisotopes; 0/Heterocyclic Compounds, 1-Ring; 0/J591 monoclonal antibody; 0/MDV 3100; 0/Radiopharmaceuticals; 0/Receptors, Androgen; 2010-15-3/Phenylthiohydantoin; 521-18-6/Dihydrotestosterone; 60239-18-1/1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid; EC 220.127.116.11/Glutamate Carboxypeptidase II; EC 18.104.22.168/glutamate carboxypeptidase II, human; EC 22.214.171.124/Prostate-Specific Antigen|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Inflammatory disease protective R381Q IL23 receptor polymorphism results in decreased primary CD4+ a...
Next Document: PTEN-inducible kinase 1 (PINK1)/Park6 is indispensable for normal heart function.